Risk Factors and Clinical Impact of Carbapenem-Resistant Enterobacterales Coinfections Among Hospitalized Patients with Clostridioides difficile Infection

References

• Zhang RF, Man YX, Bai YY., et al. Molecular characterization of Clostridioides difficile ribotype 027 in a major Chinese hospital. J Microbiol Immunol Infect. 2021;54(6):1179–1183. doi:10.1016/j.jmii.2021.01.003
   PubMedGoogle Scholar
• Lee JC, Hung YP, Tsai BY, et al. Severe Clostridium difficile infections in intensive care units: diverse clinical presentations. J Microbiol Immunol Infect. 2021;54(6):1111–1117. doi:10.1016/j.jmii.2020.07.012
   PubMedGoogle Scholar
• Chang TH, Hsu WY, Yang TI, et al. Increased age and proton pump inhibitors are associated with severe Clostridium difficile infections in children. J Microbiol Immunol Infect. 2020;53(4):578–584. doi:10.1016/j.jmii.2018.09.002
   PubMedGoogle Scholar
• Hung YP, Lee JC, Tsai BY, et al. Risk factors of Clostridium difficile-associated diarrhea in hospitalized adults: vary by hospitalized duration. J Microbiol Immunol Infect. 2021;54(2):276–283. doi:10.1016/j.jmii.2019.07.004
   PubMedGoogle Scholar
• Hung YP, Tsai CS, Tsai BY, et al. Clostridioides difficile infection in patients with hematological malignancy: a multicenter study in Taiwan. J Microbiol Immunol Infect. 2021;54(6):1101–1110. doi:10.1016/j.jmii.2021.02.002
   PubMedGoogle Scholar
• Lin TC, Hung YP, Ko WC, et al. Fecal microbiota transplantation for Clostridium difficile infection in Taiwan: establishment and implementation. J Microbiol Immunol Infect. 2019;52(6):841–850. doi:10.1016/j.jmii.2019.08.009
   Google Scholar
• Wu KS, Syue LS, Cheng A, et al. Recommendations and guidelines for the treatment of Clostridioides difficile infection in Taiwan. J Microbiol Immunol Infect. 2020;53(2):191–208. doi:10.1016/j.jmii.2020.02.002
   PubMedGoogle Scholar
• Chang FC, Liu CP, Sun FJ, et al. Optimizing laboratory workflow for the diagnosis of Clostridiodes difficile infection in a medical center in Northern Taiwan. J Microbiol Immunol Infect. 2021;54(2):284–289. doi:10.1016/j.jmii.2019.08.004
   Google Scholar
• Lai YH, Tsai BY, Hsu CY, et al. The role of Toll-Like receptor-2 in Clostridioides difficile infection: evidence from a mouse model and clinical patients. Front Immunol. 2021;12:691039. doi:10.3389/fimmu.2021.691039
   PubMed Web of Science ®Google Scholar
• Chiu CW, Tsai PJ, Lee CC, et al. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability? J Microbiol Immunol Infect. 2021;54(6):1011–1017. doi:10.1016/j.jmii.2021.06.002
   PubMedGoogle Scholar
• Lee CC, Lee JC, Chiu CW, et al. Clinical significance of toxigenic Clostridioides difficile growth in stool cultures during the era of nonculture methods for the diagnosis of C. difficile infection. Microbiol Spectr. 2021;9(2):e0079921. doi:10.1128/Spectrum.00799-21
   PubMed Web of Science ®Google Scholar
• Di Tommaso N, Gasbarrini A, Ponziani FR. Intestinal barrier in human health and disease. Int J Environ Res Public Health. 2021;18(23):12836. doi:10.3390/ijerph182312836
   PubMed Web of Science ®Google Scholar
• Giuffre M, Campigotto M, Campisciano G, et al. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature. Am J Physiol Gastrointest Liver Physiol. 2020;318(5):G889–G906. doi:10.1152/ajpgi.00161.2019
   PubMed Web of Science ®Google Scholar
• Giuffre M, Moretti R, Campisciano G, et al. You talking to me? Says the enteric nervous system (ENS) to the microbe. How intestinal microbes interact with the ENS. J Clin Med. 2020;9(11):3705. doi:10.3390/jcm9113705
   Web of Science ®Google Scholar
• Yamaguchi T, Konishi H, Aoki K, et al. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin. J Infect Chemother. 2020;26(5):483–491. doi:10.1016/j.jiac.2019.12.020
   Web of Science ®Google Scholar
• Wuethrich I, Khodamoradi Y, Vehreschild M. The role of the human gut microbiota in colonization and infection with multidrug-resistant bacteria. Gut Microbes. 2021;13(1):1–13. doi:10.1080/19490976.2021.1911279
   PubMed Web of Science ®Google Scholar
• Lin TC, Hung YP, Lin WT, et al. Risk factors and clinical impact of bacteremia due to carbapenem-nonsusceptible Enterobacteriaceae: a multicenter study in southern Taiwan. J Microbiol Immunol Infect. 2021;54(6):1122–1129. doi:10.1016/j.jmii.2021.05.005
   Google Scholar
• Korach-Rechtman H, Hreish M, Fried C, et al. Intestinal dysbiosis in carriers of carbapenem-resistant Enterobacteriaceae. mSphere. 2020;5(2):e00173–20. doi:10.1128/mSphere.00173-20
   PubMed Web of Science ®Google Scholar
• Piewngam P, Quinones M, Thirakittiwatthana W, et al. Composition of the intestinal microbiota in extended-spectrum beta-lactamase-producing Enterobacteriaceae carriers and non-carriers in Thailand. Int J Antimicrob Agents. 2019;53(4):435–441. doi:10.1016/j.ijantimicag.2018.12.006
   Web of Science ®Google Scholar
• Saavedra SY, Bernal JF, Montilla-Escudero E, et al. Complexity of genomic epidemiology of carbapenem-resistant Klebsiella pneumoniae isolates in Colombia urges the reinforcement of whole genome sequencing-based surveillance programs. Clin Infect Dis. 2021;73(Suppl4):S290–S299. doi:10.1093/cid/ciab777
   Web of Science ®Google Scholar
• Nagaraj G, Shamanna V, Govindan V, et al. High-resolution genomic profiling of carbapenem-resistant Klebsiella pneumoniae isolates: a multicentric retrospective Indian study. Clin Infect Dis. 2021;73(Suppl4):S300–S307. doi:10.1093/cid/ciab767
   Web of Science ®Google Scholar
• Jean SS, Lee NY, Tang HJ, et al. Carbapenem-resistant Enterobacteriaceae infections: Taiwan aspects. Front Microbiol. 2018;9:2888. doi:10.3389/fmicb.2018.02888
   Web of Science ®Google Scholar
• Chang YY, Chuang YC, Siu LK, et al. Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: a nationwide multicenter study in Taiwan. J Microbiol Immunol Infect. 2015;48(2):219–225. doi:10.1016/j.jmii.2014.05.010
   PubMedGoogle Scholar
• Prasad N, Labaze G, Kopacz J, et al. Asymptomatic rectal colonization with carbapenem-resistant Enterobacteriaceae and Clostridium difficile among residents of a long-term care facility in New York City. Am J Infect Control. 2016;44(5):525–532. doi:10.1016/j.ajic.2015.11.021
   Web of Science ®Google Scholar
• Giacobbe DR, Del Bono V, Mikulska M, et al. Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy. Infection. 2017;45(6):849–856. doi:10.1007/s15010-017-1063-7
   PubMed Web of Science ®Google Scholar
• Wang M, Earley M, Chen L, et al. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infect Dis. 2022;22(3):401–412. doi:10.1016/S1473-3099(21)00399-6
   PubMed Web of Science ®Google Scholar
• Chen IR, Huang PH, Wu PF, et al. Clinical characteristics and outcomes of 56 patients with pneumonia caused by carbapenem-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist. 2021;25:326–330. doi:10.1016/j.jgar.2021.03.028
   PubMed Web of Science ®Google Scholar
• Zhang H, Guo Z, Chai Y, et al. Risk Factors for and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae nosocomial infections: a retrospective study in a tertiary hospital in Beijing, China. Infect Drug Resist. 2021;14:1393–1401. doi:10.2147/IDR.S298530
   PubMed Web of Science ®Google Scholar
• The Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. In: CLSI Supplement M100. 31th. The Clinical and Laboratory Standards Institute; 2019
   Google Scholar
• Lim FK, Liew YX, Cai Y, et al. Treatment and outcomes of infections caused by diverse carbapenemase-producing carbapenem-resistant Enterobacterales. Front Cell Infect Microbiol. 2020;10:579462. doi:10.3389/fcimb.2020.579462
   Web of Science ®Google Scholar
• Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693–1703. doi:10.1056/NEJMoa1012413
   PubMed Web of Science ®Google Scholar
• Hung YP, Cia CT, Tsai BY, et al. The first case of severe Clostridium difficile ribotype 027 infection in Taiwan. J Infect. 2015;70(1):98–101. doi:10.1016/j.jinf.2014.08.003
   PubMed Web of Science ®Google Scholar
• Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089–2100. doi:10.1111/j.1523-1755.2005.00365.x
   PubMed Web of Science ®Google Scholar
• Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029–e1044. doi:10.1093/cid/ciab549
   PubMed Web of Science ®Google Scholar
• Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302. doi:10.1086/519265
   PubMed Web of Science ®Google Scholar
• Ponte A, Pinho R, Mota M. Fecal microbiota transplantation: is there a role in the eradication of carbapenem-resistant Klebsiella pneumoniae intestinal carriage? Rev Esp Enferm Dig. 2017;109(5):392. doi:10.17235/reed.2017.4425/2016
   Web of Science ®Google Scholar
• Zhang H, Wang J, Zhou W, et al. Risk factors and prognosis of carbapenem-resistant Klebsiella pneumoniae infections in respiratory intensive care unit: a retrospective study. Infect Drug Resist. 2021;14:3297–3305. doi:10.2147/IDR.S317233
   PubMed Web of Science ®Google Scholar
• Zhu WM, Yuan Z, Zhou HY. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection relative to two types of control patients: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2020;9(1):23. doi:10.1186/s13756-020-0686-0
   Web of Science ®Google Scholar
• Xiao T, Zhu Y, Zhang S, et al. A retrospective analysis of risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae bacteremia in nontransplant patients. J Infect Dis. 2020;221(Suppl2):S174–S183. doi:10.1093/infdis/jiz559
   Web of Science ®Google Scholar
• Lapp Z, Han JH, Wiens J, et al. Patient and microbial genomic factors associated with carbapenem-resistant Klebsiella pneumoniae extraintestinal colonization and infection. mSystems. 2021;6(2):e00177–21. doi:10.1128/mSystems.00177-21
   Web of Science ®Google Scholar
• Rodriguez-Villodres A, Martin-Gandul C, Penalva G, et al. Prevalence and risk factors for multidrug-resistant organisms colonization in long-term care facilities around the world: a review. Antibiotics. 2021;10(6):680. doi:10.3390/antibiotics10060680
   Web of Science ®Google Scholar
• van Rossen TM, Ooijevaar RE, Vandenbroucke-Grauls C, et al. Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clin Microbiol Infect. 2022;28(3):321–331. doi:10.1016/j.cmi.2021.09.026
   Web of Science ®Google Scholar
• Finn E, Andersson FL, Madin-Warburton M. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI. BMC Infect Dis. 2021;21(1):456. doi:10.1186/s12879-021-06147-y
   Web of Science ®Google Scholar
• Medaglia AA, Buffa S, Gioe C, et al. An emergent infectious disease: Clostridioides difficile infection hospitalizations, 10-year trend in Sicily. Infection. 2021;49(6):1221–1229. doi:10.1007/s15010-021-01683-w
   Web of Science ®Google Scholar
• Bovonratwet P, Bohl DD, Malpani R, et al. Incidence, risk factors, and impact of Clostridium difficile colitis following primary total Hip and knee arthroplasty. J Arthroplasty. 2018;33(1):205–210e1. doi:10.1016/j.arth.2017.08.004
   Web of Science ®Google Scholar
• Mishima E, Abe T. Role of the microbiota in hypertension and antihypertensive drug metabolism. Hypertens Res. 2022;45(2):246–253. doi:10.1038/s41440-021-00804-0
   Web of Science ®Google Scholar
• Yin L, He L, Miao J, et al. Carbapenem-resistant Enterobacterales colonization and subsequent infection in a neonatal intensive care unit in Shanghai, China. Infect Prev Pract. 2021;3(3):100147. doi:10.1016/j.infpip.2021.100147
   PubMedGoogle Scholar
• Howard-Anderson JR, Earley M, Komarow L, et al. Poor outcomes in both infection and colonization with carbapenem-resistant Enterobacterales. Infect Control Hosp Epidemiol. 2022:1–7. doi:10.1017/ice.2022.4
   Web of Science ®Google Scholar
• Sertkaya A, Wong HH, Ertis DH, Jessup A. Societal willingness to pay to avoid mortality and morbidity from Clostridioides difficile and carbapenem-resistant Enterobacteriaceae infections in the United States. Am J Infect Control. 2019;47(5):521–526. doi:10.1016/j.ajic.2018.11.008
   Web of Science ®Google Scholar
• Wanla W, Katip W, Supakul S, Apiwatnakorn P, Khamsarn S. Effects of an antimicrobial restriction system on appropriate carbapenem use in a hospital without infectious diseases consultation. Int J Gen Med. 2017;10:443–449. doi:10.2147/IJGM.S145133
   PubMed Web of Science ®Google Scholar